Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

“Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both Type 1 and Type 2 diabetes, following recent FDA clearance for the Type 2 label indication. Insulet leads the ...

Revenue grew 26% to $543.9 million, ahead of the $519.5 that analysts forecast. Chief Executive Jim Hollingshead said the company's Omnipod 5 automated insulin delivery system -- which was cleared by ...

The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The ...

Revolutionary glucose-responsive insulin NNC2215 offers hope for diabetics, managing blood sugar levels without hypoglycemia ...

As pharmaceutical companies strive to expand access to medications in emerging markets, low-cost, easy-to-use drug delivery ...